Brief: WPD Pharmaceuticals Enters Into Amended And Restated Sublicense Agreement With Moleculin Biotech
25/01/2022 13:19
Jan 25 (Reuters) - WPD Pharmaceuticals Inc WBIO.CD :
* WPD PHARMACEUTICALS ENTERS INTO AMENDED AND RESTATED
SUBLICENSE
AGREEMENT WITH MOLECULIN BIOTECH
Source text for Eikon: ID:nGNX8LQWdM
Further company coverage: WBIO.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on WPD Pharmaceuticals
See all newsBrief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Signs About 2 Mln Zloty Deal With WPD Pharmaceuticals
Brief: WPD Pharmaceuticals Signs Annex To License Agreement With Wake Forest University Health Sciences
Brief: WPD Pharmaceuticals Announces Proposed Restructuring Of Polish Subsidiary
Brief: WPD Pharmaceuticals Enters Into Amended And Restated Sublicense Agreement With Moleculin Biotech